Recent research indicates that in melanoma driven by B-type Raf kinase (BRAF) mutations, resistance to inhibitors of the mitogen-activated protein kinases (MAPK) pathway may arise through macrophage-secreted Tumor Necrosis Factor alpha (TNF-α) (37). Here, WNK2 is linked to melanoma.